- New candidate drug molecules identified by pharmaceutical companies through AI;
- New alloy formulas discovered by material laboratories;
- Optimized circuit architectures developed by chip design teams;
- Even new products incubated by startups based on AI-generated ideas.
This is not a capability that will go unused.
No. You see, the money is supposed to go to Altman.
Instead, it's advertising and speculation.
> Your business model might end up being sort of a … startup incubator or private equity firm; you’d spend your time starting or acquiring companies on which the robot could work its magic. Your business model would be “general business, but with AI”.. Either it will sell AI at high margins to lots of businesses, or it will sell AI at lower margins to lucrative businesses that it owns.
The Information is also reporting on this, but paywalled. IMO The Information does solid reporting.
https://www.theinformation.com/newsletters/applied-ai/openai...
Editing to add some of the Information’s reporting: > Speaking at a panel at Davos moderated by The Information CEO Jessica Lessin, Friar suggested that in the field of drug discovery, her company could, for instance, take a “license to the drug that is discovered” using OpenAI’s technology. In other words, OpenAI would take a profit-sharing stake in the financial upside its AI creates for customers.
> Friar is no doubt familiar with older AI drug discovery firms such as Recursion that struck deals with pharmaceutical firms to give them big bounties for successful drugs identified by their tech. There aren’t many, if any, examples of such successes yet, though.
> OpenAI isn’t the only firm eyeing this opportunity. Its rivals Anthropic, Google DeepMind and Isomorphic Labs, an Alphabet subsidiary focusing on using AI for drug discovery, have also held discussions with early-stage biotechnology startups about data licensing or partnerships.